

CERTIFICATE OF MAILING

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the: Assistant Commissioner for Patents, Washington, D.C. 20231.

Sammy G. Duncan, Jr.

Type or print name




Signature

6/22/04

Date

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



RE APPLICATION OF

ROBICHAUD ET AL.

APPLICATION NO: 10/786,935

FILED: FEBRUARY 25, 2004

FOR: SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES

**Mail Stop Box Amendment**

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

Applicants believe this paper is being filed before the mailing date of a first Office Action on the merits, and so under 37 C.F.R. §1.97(b)(3) no fees are required. If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-3880.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

The listed references are of record in parent Application No. 09/594,008 filed April 15, 2003, and parent Application No. 10/370,872, filed 5/13/04, and copies are available therein. However, applicants are willing to send copies of any or all of these references at the Examiner's request.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,



Sammy G. Duncan Jr., Ph.D.  
Attorney for Applicants  
Reg. No. 46,675

Bristol-Myers Squibb Company  
Patent Department  
P.O. Box 4000  
Princeton, NJ 08543-4000  
(609) 252-6270

Date: 6/20/04

JUN 24 2004

Sheet 1 of 3

Form PTO-1449  
(Reproduced)U. S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.

PH-7218A CIP

SERIAL NO.

10/786,935

## INFORMATION DISCLOSURE STATEMENT

BY APPLICANT

(Use several sheets if necessary)

APPLICANT

Robichaud et al

FILING DATE

2/25/04

GROUP

1624

## U. S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUB-CLASS	FILING DATE IF APPROPRIATE
	AA	5	5	1	2	5	7	5	4/30/1996	Jacobs et al			
	AB	5	6	5	4	1	3	9	8/5/1997	Lappalainen et al			
	AC	5	9	0	2	8	1	5	5/11/1999	Olney et al			
	AD	5	9	0	8	8	3	0	6/1/1999	Smith et al			
	AE	6	1	0	7	3	2	4	8/22/2000	Behan et al			
	AF	6	1	4	0	5	0	9	10/31/2000	Behan et al			

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER		COUNTRY	CLASS	SUB-CLASS	TRANSLATION	
							YES	NO
	AG							
	AH							

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

AI		Bickerdike MJ, Vickers, SP, Dourish CT, (1999) 5-HT2C receptor modulation and the treatment of obesity. Diabetes, Obesity and Metabolism 1:207-214
	AJ	Tecott LH, et al. (1995) Eating disorder and epilepsy in mice lacking 5-HT2C serotonin receptors. Nature (London) 374:542-546
AK		Cryan JF, Lucki I, (2000) Antidepressant-like behavioral effects mediated by 5-hydroxytryptamine2C receptors. J. Pharmacol. Exper. Ther. 295:1120-1126
AL		Millan MJ, Peglion JL, Lavielle G, Perrin-Monneyron S, (1997) 5-HT2C receptors mediate penile erection in rats: actions of novel and selective agonists and antagonists. Eur. J. Pharmacol. 325:9-12
AM		Martin JR, et al. (1998) 5-HT2C receptor agonists: Pharmacological characteristics and therapeutic potential. J. Pharmacol. Exper. Ther. 286:913-924
AN		Meltzer HY. (1999) The role of serotonin in antipsychotic drug action. Neuropsychopharmacology 21(2):1065-1155

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449  
(Reproduced)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.  
PH-7218 A CIPSERIAL NO.  
10/786,935INFORMATION DISCLOSURE STATEMENT  
BY APPLICANT  
(Use several sheets if necessary)APPLICANT  
Robichaud et alFILING DATE  
2/25/04GROUP  
1624

## U. S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE IF APPROPRIATE
	AA'						
	AB'						
	AC'						
	AD'						
	AE'						
	AF'						

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
							YES      NO
	AG'						
	AH'						

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	AI'	Curzon et al, Appetite suppression by commonly used drugs depends on 5-HT receptors but not on 5-HT availability, TiPS, Vol. 18, 1997; 21-25
	AJ'	Mora et al, Role of 5-HT2A and 5-HT2C Receptor subtypes in the Two Types of Fear Generated by the Elevated T-Maze, Pharma. Biolchem. & Behavior, Vol. 58, No. 4, 1997; 1051-1057
	AK'	Jenck et al, Antiaversive effects of 5HT2C receptor agonists and fluoxetine in a model of panic-like anxiety in rats, European Neuropsychopharmacology, 8, 1998; 161-168
	AL'	Leysen, Selective 5-HT2c agonists as potential antidepressants, Drugs, 1999, 2(2); 109-120
	AM'	Jenck et al, The role of 5-HT2c receptors in affective disorders, Exp. Opin. Invest. Drugs, 1998, 7(10); 1587-1599
	AN'	Kennett, 5-HT drugs and eating disorders, I Drugs, 1998, Vol. 1, No. 4; 456-470

EXAMINER \_\_\_\_\_ DATE CONSIDERED \_\_\_\_\_

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449  
(Reproduced)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.

SERIAL NO.

PH-7218A CIP

10/786,935

APPLICANT

Robichaud et al

FILING DATE

2/25/04

GROUP

1624

## INFORMATION DISCLOSURE STATEMENT

BY APPLICANT

(Use several sheets if necessary)

## U. S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE IF APPROPRIATE
	AA"	3 2 9 9 0 7 8	1/17/67	Pachter			
	AB"						
	AC"						
	AD"						
	AE"						
	AF"						

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
							YES
	AG"						
	AH"						

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	AI"	Brewerton, Induction of migrainelike headaches by the serotonin agonist m-chlorophenylpiperazine, Clin. Pharmacol. Ther., 1988, 605-609
	AJ"	Kahn et al, m-Chlorophenylpiperazine as a probe of serotonin function, Biol. Psychiatry, 1991; 30: 1139-1166
	AK"	Gibson et al, Evidence that mCPP-induced Anxiety in the Plus-maze is mediated by Postsynaptic 5-HT2c receptors but not by sympathomimetic effects, Neuropharmacology, Vol. 33, No. 3, 4, 1994; 457-465
	AL"	
	AM"	
	AN"	

EXAMINER DATE CONSIDERED

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.